# A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

> **NCT05330065** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 55 (estimated)

## Conditions studied

- Malignant Pleural Effusion

## Interventions

- **DRUG:** bevacizumab and camrelizumab

## Key facts

- **NCT ID:** NCT05330065
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330065, "A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05330065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*